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See Article, pages 441–447Hepatic steatosis is one of the earliest and most consistent
changes which occur with excessive consumption of alcohol.
The development of steatosis is known to sensitize the liver to
other insults, and is an important step towards the development
of the full spectrum of alcohol-induced liver pathologies [1]. The
combination of high energy consumption by hepatocytes, and the
venous inﬂow into the liver place hepatocytes at risk of hypoxia.
Alcohol consumption was shown to increase hepatic oxygen con-
sumption, with a smaller increase in hepatic oxygen delivery,
resulting in central venous hypoxia [2]. These ﬁndings bring
together the ﬁelds of alcoholic liver disease and tissue adaptation
to hypoxia. Adaptation to low oxygen tension is known to be reg-
ulated by transcriptional induction of genes important in myriad
biological processes including metabolism, angiogenesis, cell
cycle regulation, and cell death. The hypoxia inducible factor
(HIF) family of heterodimeric transcription factors is important
in regulating these processes [3]. Functional HIF is composed of
an alpha unit (HIF-1a, HIF-1b, or HIF-3a), and a HIF-1b subunit.
Under normal conditions, the alpha units are rapidly degraded
in the cytosol, but under hypoxic conditions they escape degrada-
tion, dimerise with the b unit, translocate to the nucleus, and reg-
ulate numerous gene transcription programs [4].
In this issue of the Journal, Dr. Nishiyama and colleagues
address the question of the role of HIF-1a in the metabolic and
histological changes associated with alcoholic liver disease [5].
They employ a sophisticated but well established technique of
hepatocyte speciﬁc HIF-1a deletion, and demonstrate that, in a
model of alcohol-induced liver disease in mice, there is an up-
regulation of HIF-1a in a central venous distribution, and, in
the absence of hepatocyte HIF-1a, there is greater pathology with
increased liver weight, steatosis and increased liver and serum
triglycerides. This is strong evidence that the alcohol-induced
increase in hepatic HIF-1a is adaptive and protective. To under-
stand which genes are regulated by HIF-1a in this alcohol-
induced liver disease model, the authors identiﬁed changes in
expression levels of genes known to be important in lipid metab-
olism, and found higher expression levels for a number of lipo-Journal of Hepatology 20
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sustained elevation, they focused on two genes coding for the lip-
ogenic proteins SREBP-1c, and its downstream target ACC. A HIF-
1a-induced transcriptional regulator repressor DECI was demon-
strated to be important for maintaining a lower level of SREBP-1c
in wild-type mice.
A recent study also found that an alcohol rich diet up-regu-
lates HIF-1a in mice, but subsequently demonstrated that HIF-
1a, rather than inducing adaptive and protective changes from
the development of steatosis, is a key step in the development
of steatosis and hypertriglyceridemia [6]. This study used two
genetic manipulations, one in which there was constitutively
active HIF-1a in hepatocytes, and a second that used the same
hepatocyte speciﬁc HIF-1a deletion approach as above. Both
genetic manipulations gave concordant results, with mice
expressing constitutively active HIF-1a in hepatocytes develop-
ing increased liver steatosis and hypertriglyceridemia, and mice
lacking HIF-1a in hepatocytes having reduced liver steatosis
and hypertriglyceridemia.
Both studies used similar and at times near identical technol-
ogies, and the reasons for the opposite ﬁndings are not obvious.
Focusing on potential weak points, over-expression studies are
at risk of not capturing the scale, timing and tissue distribution
of native expression. This is certainly possible for HIF-1a which
has a zonal distribution, and expression peaks one hour after
hypoxia [5,7]. The discordant results between the two studies
when using the same mice lacking HIF-1a in hepatocytes are
much more difﬁcult to explain. There are differences in the diets
used, and also in the choice of controls which appear minor.
Nishiyama et al. used littermate HIF-1a ﬂoxed mice without Alb-
Cre transgene as controls, and Nath et al. used wild-type mice. An
analogous discrepancy is present in the literature for c-Jun N ter-
minal kinase 2 (JNK2) deleted mice with acetaminophen (APAP)
toxicity. One group demonstrated that JNK2/ mice had greater
susceptibility to APAP toxicity, and another group demonstrated
JNK2/ mice had reduced susceptibility [8,9]. This was resolved
by the careful demonstration that differences in mouse sub-
strains, which were not recognized by the two groups and by
the vendor, made the crucial difference [9]. Finally, there are
likely different colonic ﬂora in in-house and purchased mice,
which may result in different responses to alcohol feeding and12 vol. 56 j 311–312
Editorial
gut endotoxin permeability, such that there is a greater TLR4 sig-
nal along with ethanol in one colony compared to another. Differ-
ences in colic ﬂora have recently been shown to have a major
effect on colitis phenotypes [10]. There is no reason to believe
that any of these factors are relevant here or in many other stud-
ies, however, when faced with such different results, future stud-
ies on HIF-1a would hopefully remove such potentially
confounding factors.
A different approach to address these data is to compare
which model ﬁts best with the other published data on HIF-1a
and liver pathology. For other pathological responses is HIF-1a
responsible for adaptive changes which counter a pathological
insult, or is it a key step which converts the signal from the path-
ologic stressor to a full pathologic phenotype? Staying with mod-
els of alcohol induced injury, if we examine the inﬂammatory
responses, the role of HIF-1a has been studied for up-regulation
of RANTES/CCL5, which is a member of the superfamily of proin-
ﬂammatory cytokines referred to as the CC chemokine family,
and it is chemoattractant for T lymphocytes, monocytes, and
macrophages. The upregulation of RANTES/CCL5 is in part due
to HIF-1a, suggesting a direct role for HIF-1a in the alcohol
induced inﬂammatory response [11]. Ethanol also induces
increases in portal pressure which is dependent on upregulation
of endothelin-1, which is mediated by HIF-1a. This suggests that
HIF-1a is a mediator towards the development of a pro-inﬂam-
matory and vasoconstrictive phenotype in alcoholic liver disease
[12].
Chronic hypoxia is also known to occur in many models of
liver ﬁbrosis, and as expected, HIF-1a is activated in ﬁbrotic liv-
ers. In a model of bile duct ligation induced ﬁbrosis, inducible
deletion of HIF-1a resulted in lower levels of several pro-ﬁbro-
genic mediators, less a-smooth muscle actin, less hepatic colla-
gen and reduced liver ﬁbrosis [13]. Liver ﬁbrosis is also
associated with angiogenesis, and analogous to a role in liver
ﬁbrosis, in the absence of HIF-1a there was a signiﬁcant reduc-
tion in up-regulation of the vascular endothelial growth factor.
In hepatic inﬂammation, portal hypertension, liver ﬁbrosis,
and angiogenesis, HIF-1a appears to be a mediator of the disease
phenotype, rather than a regulator against it. In relation to stea-
tosis, a recent study suggests that the situation may be more
complex than a simple binary analysis of whether HIF-1a is driv-
ing pathological phenotype, or protecting against it. A factor
inhibiting HIF-1a (FIH) blocks the association of HIFs with tran-
scriptional co-activators, thus inhibiting HIF mediated transcrip-
tional activation. FIH null mice have increased HIF functionality,
and a large range of metabolic changes including a higher meta-
bolic rate, hyperventilation, improved glucose control and resis-
tance to high-fat-diet-induced steatosis [14]. The question of
whether these changes in FIH null mice are due to increased
HIF mediated transcription, or to additional pathways still needs
to be addressed.
Collectively, these studies demonstrate hepatic HIF-1a is
increased in mice after an alcohol rich diet and manipulation of
HIF-1a in vivo has profound effects on the steatotic and metabolic
phenotypes after high alcohol consumption. As HIF-1a is a tran-
scription regulator rather than a receptor ligand or enzyme, it is
not surprising that the results of changing HIF-1a activity are312 Journal of Hepatology 201complex, and may be very dependent on which other signals
the hepatocyte is receiving at the same time. Unraveling these
complexities will be very challenging, and may require
approaches analogous to other complex problems such as study
of drug induced toxicity. Signiﬁcant progress has been made with
novel approaches such a network of investigators rather than
individual laboratories [15].Conﬂict of interest
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